201 related articles for article (PubMed ID: 17380112)
1. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions.
Redondo P; del Olmo J; López-Diaz de Cerio A; Inoges S; Marquina M; Melero I; Bendandi M
J Invest Dermatol; 2007 Jul; 127(7):1673-80. PubMed ID: 17380112
[TBL] [Abstract][Full Text] [Related]
2. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
[TBL] [Abstract][Full Text] [Related]
3. Imiquimod combined with dendritic cell vaccine decreases Treg proportion and enhances anti-tumor responses in mice bearing melanoma.
Ren S; Wang Q; Zhang Y; Lu C; Li P; Li Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Feb; 33(2):145-50. PubMed ID: 29762000
[TBL] [Abstract][Full Text] [Related]
4. Cryosurgery during topical imiquimod: a successful combination modality for lentigo maligna.
Bassukas ID; Gamvroulia C; Zioga A; Nomikos K; Fotika C
Int J Dermatol; 2008 May; 47(5):519-21. PubMed ID: 18412875
[TBL] [Abstract][Full Text] [Related]
5. Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance.
Thatcher TH; Luzina I; Fishelevich R; Tomai MA; Miller RL; Gaspari AA
J Invest Dermatol; 2006 Apr; 126(4):821-31. PubMed ID: 16439962
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors.
Aranda F; Llopiz D; Díaz-Valdés N; Riezu-Boj JI; Bezunartea J; Ruiz M; Martínez M; Durantez M; Mansilla C; Prieto J; Lasarte JJ; Borrás-Cuesta F; Sarobe P
Cancer Res; 2011 May; 71(9):3214-24. PubMed ID: 21402711
[TBL] [Abstract][Full Text] [Related]
7. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ
J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767
[TBL] [Abstract][Full Text] [Related]
8. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer.
Dewan MZ; Vanpouille-Box C; Kawashima N; DiNapoli S; Babb JS; Formenti SC; Adams S; Demaria S
Clin Cancer Res; 2012 Dec; 18(24):6668-78. PubMed ID: 23048078
[TBL] [Abstract][Full Text] [Related]
9. The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine.
Craft N; Bruhn KW; Nguyen BD; Prins R; Lin JW; Liau LM; Miller JF
J Immunol; 2005 Aug; 175(3):1983-90. PubMed ID: 16034143
[TBL] [Abstract][Full Text] [Related]
10. Imiquimod enhances the potency of an exogenous BM-DC based vaccine against mouse melanoma.
Ren S; Wang Q; Zhang Y; Song Y; Dong X; Zhang W; Qin X; Liu M; Yu T
Int Immunopharmacol; 2018 Nov; 64():69-77. PubMed ID: 30149266
[TBL] [Abstract][Full Text] [Related]
11. The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma.
Cho JH; Lee HJ; Ko HJ; Yoon BI; Choe J; Kim KC; Hahn TW; Han JA; Choi SS; Jung YM; Lee KH; Lee YS; Jung YJ
Oncotarget; 2017 Apr; 8(15):24932-24948. PubMed ID: 28212561
[TBL] [Abstract][Full Text] [Related]
12. In situ tumor ablation creates an antigen source for the generation of antitumor immunity.
den Brok MH; Sutmuller RP; van der Voort R; Bennink EJ; Figdor CG; Ruers TJ; Adema GJ
Cancer Res; 2004 Jun; 64(11):4024-9. PubMed ID: 15173017
[TBL] [Abstract][Full Text] [Related]
13. Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine.
Johnston D; Bystryn JC
Vaccine; 2006 Mar; 24(11):1958-65. PubMed ID: 16310898
[TBL] [Abstract][Full Text] [Related]
14. Combination of cryosurgery and topical imiquimod: does timing matter for successful immunocryosurgery?
Bassukas ID; Gaitanis G
Cryobiology; 2009 Aug; 59(1):116-7. PubMed ID: 19426725
[No Abstract] [Full Text] [Related]
15. Targeting ALCAM in the cryo-treated tumour microenvironment successfully induces systemic anti-tumour immunity.
Kudo-Saito C; Fuwa T; Kawakami Y
Eur J Cancer; 2016 Jul; 62():54-61. PubMed ID: 27208904
[TBL] [Abstract][Full Text] [Related]
16. Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha?
Urosevic M; Oberholzer PA; Maier T; Hafner J; Laine E; Slade H; Benninghoff B; Burg G; Dummer R
Clin Cancer Res; 2004 Aug; 10(15):4959-70. PubMed ID: 15297396
[TBL] [Abstract][Full Text] [Related]
17. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.
Adams S; O'Neill DW; Nonaka D; Hardin E; Chiriboga L; Siu K; Cruz CM; Angiulli A; Angiulli F; Ritter E; Holman RM; Shapiro RL; Berman RS; Berner N; Shao Y; Manches O; Pan L; Venhaus RR; Hoffman EW; Jungbluth A; Gnjatic S; Old L; Pavlick AC; Bhardwaj N
J Immunol; 2008 Jul; 181(1):776-84. PubMed ID: 18566444
[TBL] [Abstract][Full Text] [Related]
18. TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines.
Johnston D; Zaidi B; Bystryn JC
Cancer Immunol Immunother; 2007 Aug; 56(8):1133-41. PubMed ID: 17139492
[TBL] [Abstract][Full Text] [Related]
19. Topical resiquimod promotes priming of CTL to parenteral antigens.
Chang BA; Cross JL; Najar HM; Dutz JP
Vaccine; 2009 Sep; 27(42):5791-9. PubMed ID: 19660592
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells.
Dang Y; Wagner WM; Gad E; Rastetter L; Berger CM; Holt GE; Disis ML
Clin Cancer Res; 2012 Jun; 18(11):3122-31. PubMed ID: 22510348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
